A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer
A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer
The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Capital Federal, Buenos Aires 1426, Argentina
Kita-Gun, Kagawa-ken 7610793, Japan
Takatsuki-shi, Osaka 5698686, Japan
Hamamatasu, Shizuoka 431-3192, Japan
Adachi-ku, Tokyo 1168567, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Bunkyo-ku, Tokyo 1138602, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Lorenskog, 1478, Norway